Tempest Therapeutics Statistics
Total Valuation
TPST has a market cap or net worth of $33.70 million. The enterprise value is $19.44 million.
Important Dates
The last earnings date was Thursday, March 27, 2025, after market close.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPST has 43.64 million shares outstanding. The number of shares has increased by 80.99% in one year.
| Current Share Class | 43.64M |
| Shares Outstanding | 43.64M |
| Shares Change (YoY) | +80.99% |
| Shares Change (QoQ) | +58.85% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 7.57% |
| Float | 40.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.93 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.80.
| Current Ratio | 2.21 |
| Quick Ratio | 2.13 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.93 |
Financial Efficiency
Return on equity (ROE) is -182.35% and return on invested capital (ROIC) is -64.13%.
| Return on Equity (ROE) | -182.35% |
| Return on Assets (ROA) | -56.43% |
| Return on Invested Capital (ROIC) | -64.13% |
| Return on Capital Employed (ROCE) | -154.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.46M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.70% in the last 52 weeks. The beta is -2.57, so TPST's price volatility has been lower than the market average.
| Beta (5Y) | -2.57 |
| 52-Week Price Change | -78.70% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 41.94 |
| Average Volume (20 Days) | 436,104 |
Short Selling Information
The latest short interest is 2.11 million, so 4.83% of the outstanding shares have been sold short.
| Short Interest | 2.11M |
| Short Previous Month | 2.60M |
| Short % of Shares Out | 4.83% |
| Short % of Float | 5.27% |
| Short Ratio (days to cover) | 3.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.03M |
| Pretax Income | -31.75M |
| Net Income | -41.84M |
| EBITDA | -41.64M |
| EBIT | -42.03M |
| Earnings Per Share (EPS) | -$1.50 |
Full Income StatementBalance Sheet
The company has $30.27 million in cash and $15.37 million in debt, giving a net cash position of $14.90 million or $0.34 per share.
| Cash & Cash Equivalents | 30.27M |
| Total Debt | 15.37M |
| Net Cash | 14.90M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 19.13M |
| Book Value Per Share | 0.43 |
| Working Capital | 17.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.03 million and capital expenditures -$435,000, giving a free cash flow of -$33.46 million.
| Operating Cash Flow | -33.03M |
| Capital Expenditures | -435,000 |
| Free Cash Flow | -33.46M |
| FCF Per Share | -$0.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |